Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InNexus Biotechnology has said that Royalty Pharma will purchase a royalty interest in up to two products targeting cancer based on its Dynamic Cross Linking antibody enhancement technology.
Subscribe to our email newsletter
Under the terms of the agreement, Royalty Pharma will purchase the first royalty interest for $2 million and will hold an option to purchase a royalty interest in a second product for an additional $2 million. In addition, Royalty Pharma will make an at-market equity investment in InNexus in the amount of $1 million. The total purchase price for the royalty interests may be increased by up to $30 million for the two products if certain conditions are fulfilled.
“We believe InNexus’ DXL antibody therapeutics may lead to exciting new product candidates for cancer and other treatments. This is another example of our unique position to collaborate with companies and expand our existing portfolio of royalty interests,” stated Pablo Legorreta, CEO of Royalty Pharma.